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Background: Cardiovascular risk stratification of asymptomatic diabetic patients is important and remains a difficult
clinical problem. Our aim was to test the hypothesis that coronary flow reserve (CFR) assessed by noninvasive
transthoracic Doppler echocardiography predicts prognosis in those patients.
Methods: From February 2002 to January 2005, we evaluated 135 consecutive asymptomatic patients (74 male;
mean age, 63 ± 9 years) with type 2 diabetes without a history of coronary artery disease. Adenosine triphosphate
(0.14 mg/kg/min) stress Doppler echocardiography was performed to evaluate CFR of the left anterior descending
artery. Patients with a CFR < 2.0 were also excluded based on the suspicion of significant coronary artery stenosis in
the left anterior descending artery.
Results: There were 111 patients (60 male; mean age, 64 ± 9 years) enrolled. During a median follow-up of 79 months,
20 events (5 deaths, 7 acute coronary syndromes, 8 coronary revascularizations) occurred. The optimal cut-off value of
CFR to predict events was 2.5 (area under the receiver-operating characteristic curve = 0.65). Multivariate analysis
showed that the independent prognostic indicators were male gender (p < 0.05) and a CFR < 2.5 (p < 0.01).
Kaplan-Mayer analysis revealed that the event rate was significantly higher (log-lank, p < 0.01) in patients with
CFR < 2.5 than in those with CFR ≥ 2.5.
Conclusions: CFR obtained by transthoracic Doppler echocardiography provides independent prognostic
information in asymptomatic patients with type 2 diabetes without overt coronary artery disease. Patients with
CFR < 2.5 had a worse long-term outcome.
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The prevention of cardiovascular complications is a cru-
cial goal in the treatment of diabetes, because the inci-
dence of coronary artery disease (CAD) in patients with
type 2 diabetes is increasing worldwide as well as in
Japan [1]. Likewise, it is important to identify patients at
high risk for developing cardiovascular complications in
order to reduce morbidity and mortality. However, car-
diovascular risk stratification of patients with diabetes
remains a difficult clinical problem.
Coronary flow reserve (CFR), estimated as the ratio of
maximal hyperemic to basal coronary flow velocity, is an
important physiological parameter in the coronary cir-
culation that reflects the function of large epicardial
arteries and the microcirculation. Previous reports have
shown that noninvasive evaluation of CFR by transtho-
racic echocardiography is a useful tool to predict cardio-
vascular events in patients with cardiovascular diseases
such as hypertension [2], CAD [3], and cardiomyopathy
[4,5]. With regard to diabetes, Cortigiani and co-workers
reported that CFR ≤ 2.0 in response to high-dose dipyrid-
amole (0.84 mg/kg/min) provided prognostic information
in diabetic and non-diabetic patients with known or
suspected CAD [6]. Although they excluded patients with
myocardial ischemia using dipyridamole stress echocardi-
ography, they included patients with known CAD (i.e., his-
tory of myocardial infarction, coronary revascularization
and/or angiographic evidence of > 50% diameter coronary
stenosis) or regional wall motion abnormalities. They also
reported in another paper [2] that CFR ≤ 1.91 was the best
value for diagnosing coronary stenosis of ≥ 75% in hyper-
tensive and normotensive patients (including diabetics)
with known or suspected CAD. Therefore, in their study
[6] of CFR in diabetic patients, patients with CFR ≤ 2.0
may have had significant coronary artery stenosis. As a
result, the events that occurred during follow-up in their
study included events due to diabetes per se and events
due to CAD.
To avoid these limitations, we carefully enrolled asymp-
tomatic patients with diabetes without a history of CAD.
We tested the hypothesis that CFR assessed by noninva-
sive transthoracic Doppler echocardiography would pre-
dict cardiac events and prognosis, and would be useful to
stratify cardiac risk in these selected patients.
Methods
Patients and protocol
The present study was a prospective, observational study.
From February 2002 to January 2005, we enrolled 135
consecutive asymptomatic patients (74 male; mean age,
63 ± 9 years) with type 2 diabetes without a history of
cardiovascular disease. Patients were included if they met
the following inclusion criteria: outpatients with type 2
diabetes, no symptoms, no history of cardiovasculardisease, and a clinically stable condition. All patients that
met these inclusion criteria underwent two-dimensional
echocardiography and a treadmill exercise test, and pa-
tients who had wall motion abnormalities, atrial fibrilla-
tion, left ventricular (LV) hypertrophy (wall thickness at
end-diastole > 12 mm), valvular heart disease or a positive
treadmill test were excluded from follow-up. Furthermore,
patients with CFR < 2.0 were also excluded on the suspi-
cion of significant coronary artery stenosis in the left
anterior descending coronary artery (LAD) based on the
results of previous studies [7,8].
All subjects were studied after an overnight fast and
refrained from caffeine intake for more than 12 hours,
since caffeine may modulate the effects of adenosine.
Medical treatments, such as antihypertensive agents and
statins were continued except antidiabetic agents during
acquisition of all study data including treadmill testing.
Venous blood sampling and coronary flow velocity mea-
surements were carried out after informed consent was
obtained. The outcome of the present study was clinical
events during follow-up. Death from all causes, acute
coronary syndrome (ACS) and coronary revascularization
were considered clinical events. The protocol was ap-
proved by the committee on medical ethics and clinical
investigation of Chiba University Hospital.
Coronary risk factors
Venous blood samples were drawn from a peripheral
vein immediately before coronary flow velocity measure-
ments for determination of serum creatinine, fasting
blood sugar, glycosylated hemoglobin, and lipid profiles
(triglycerides, high-density lipoprotein cholesterol and
low-density lipoprotein cholesterol). The diagnosis of
diabetes was assured in all patients by determination of
glucose in the fasting state based on the criteria of the
World Health Organization [9]. Dyslipidemia was de-
fined as low-density lipoprotein cholesterol ≥ 140 mg/dl
or high-density lipoprotein cholesterol < 40 mg/dl or
triglycerides ≥ 150 mg/dl or already receiving medical
treatment. Arterial hypertension was defined as systolic
blood pressure above 140 mmHg or diastolic blood
pressure above 90 mmHg, or already receiving medical
treatment. Smoking habit was confirmed by a personal
interview.
Treadmill exercise test
A treadmill exercise test was performed using the Bruce
protocol. A 12-lead electrocardiogram was continuously
monitored during the test, and blood pressure was
recorded at rest and every 2 minutes during exercise and
recovery. Exercise was terminated when subjects
achieved their target heart rate, defined as 85% of the
age-predicted maximal heart rate. Any change in the ST
segment was automatically measured 80 ms after the J
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ered positive if the ST segment was horizontal or had a
downslope with a 1-mm depression.
Echocardiography
Echocardiographic examinations were performed with a
SONOS 5500 digital ultrasound system (Philips Medical
Systems, Andover, MA). LV ejection fraction was calcu-
lated with Simpson’s method using the 2 and 4 chamber
views. M-mode echocardiography was performed to
measure LV mass. The ultrasound beam was aligned
perpendicular to the interventricular septum and the
posterior wall at a level slightly below the mitral leaflet
tips. LV mass was calculated from measurements of the
septal (SD) and posterior wall thickness (PD), and LV
dimensions (LVID) at end-diastole using the following
formula [10]: 1.04 × ([SD + LVID + PD]3 − [LVID]3) – 13.6.
The LV mass calculated using this formula was indexed
to body surface area.
The method of CFR measurement with transthoracic
Doppler echocardiography was described previously
[7,8]. Coronary blood flow velocity in the distal portion
of the LAD was measured with a high frequency trans-
ducer (5 to 7 MHz) using the guidance of color Doppler
flow mapping. With a sample volume (2.5 or 3.0 mm
wide) positioned on the color signal in the LAD, Doppler
spectral tracings of flow velocity in the LAD were recorded
using a fast Fourier transformation. We first recorded
baseline spectral Doppler signals in the LAD, then intra-
venous adenosine was administered (0.14 mg/kg/min) to
record spectral Doppler signals during hyperemia. Mean
diastolic velocities (MDVs) were measured at baseline and
peak hyperemic conditions from the Doppler signal re-
cordings. Measurements were averaged over three cardiac
cycles. CFR was defined as the ratio of hyperemic to basal
MDV. To determine the reproducibility of MDV, a total of
10 randomly selected examinations were analyzed twice by
one investigator at a 1-week interval and once by another
investigator.
Follow-up data
Outcome was obtained from hospital chart reviews, and
telephone interviews with the referring physician. The
clinical events recorded during follow-up were all-cause
death, nonfatal ACS and clinically indicated coronary
revascularization (surgery or angioplasty). If more than
one of these events occurred in the same patient, the pa-
tient was censored at the time of the most severe event.
Statistical analysis
Baseline characteristics were expressed as the mean ±
standard deviation or number (%). Prediction of events
was evaluated by receiver operating characteristic curve
analysis. The cumulative event-free rates were obtainedfrom Kaplan-Meier estimates, and differences were
tested by the log-rank test. The association of selected
variables with outcome was assessed with a univariate
Cox proportional hazards model, and the variables that
were significant in the univariate model were then en-
tered into a multivariate Cox model using a forward
stepwise method. Hazard ratios (HR) with the corre-
sponding 95% confidence intervals (CI) were estimated.
Comparison of baseline characteristics between the
groups stratified according to CFR was performed with an
unpaired t test; a chi-square test was used for categorical
variables. A probability value < 0.05 was considered signifi-
cant. All data were statistically analyzed using JMP version
8.0 (SAS Institute, Cary, NC, USA).
Results
All patients who had a negative treadmill exercise test
achieved their target heart rate. There were no adverse
reactions to adenosine such as atrioventricular block,
chest pain, flushing or palpitations during coronary flow
measurement. Five patients were excluded based on
their treadmill exercise test, and 2 more were excluded
due to wall motion abnormalities. We could not obtain
LAD blood flow in 9 patients, and 7 had CFR < 2.0. Fur-
thermore, one patient refused to participate in the study.
Therefore, we enrolled 111 patients (60 male; mean age,
64 ± 9 years; BMI, 24.2 ± 3.6 kg/m2) that had adequate
coronary flow recordings for the assessment of CFR.
The interobserver and intraobserver variabilities for the
measurement of Doppler velocity were 5.0% and 3.9%,
respectively.
During a median follow-up of 79 months (range, 2 to
112 months), 20 events (5 deaths, 7 ACSs, 8 coronary
revascularizations) occurred (event rate, 3.3%/year).
From a receiver-operating characteristics curve analysis,
the optimal cut-off value of CFR to predict events was
2.5 (area under the receiver-operating characteristic
curve = 0.65). Table 1 presents patients’ general character-
istics, the results of venous blood tests, and hemodynamic
and echocardiographic data in patients stratified according
to CFR (≥ 2.5 and < 2.5). Compared with patients with
CFR ≥ 2.5, the general characteristics of the patients with
CFR < 2.5 were similar except for age, hyperemic MDV
and CFR. Table 2 presents the occurrence rate of events in
relation to CFR values.
Kaplan-Meier analysis revealed that the event rate was
significantly higher (log-lank, p < 0.01) in patients with
CFR < 2.5 than in patients with CFR ≥ 2.5 (Figure 1).
Univariate and multivariate predictors of events are
summarized in Table 3. Univariate analysis showed that
age (HR = 1.06, 95% CI = 1.01-1.12, p < 0.05), male gender
(HR = 2.59, 95% CI = 1.04-7.35, p < 0.05) and CFR < 2.5
(HR = 4.89, 95% CI = 2.02-12.5, p < 0.001) were predic-
tors of outcome. In multivariate analysis, CFR < 2.5 was
Table 1 Patients’ general characteristics and
echocardiographic data
Variables CFR ≥ 2.5, n = 82 CFR < 2.5, n = 29 p
Age (years) 62 ± 9 67 ± 9 0.02
Male 43 (52.0) 17 (59.0) 0.57
BMI (kg/m2) 24.5 ± 3.7 23.3 ± 3.1 0.11
FBS (mmol/l) 8.6 ± 2.6 8.4 ± 2.2 0.79
HbA1c (%) [NGSP] 7.7 ± 1.2 7.7 ± 1.0 0.90
eGFR (ml/min./1.73 m2) 80.6 ± 16.9 77.2 ± 19.3 0.39
Hypertension 48 (59.3) 19 (63.3) 0.51
Dyslipidemia 43 (53.1) 15 (50.0) 0.95
Smoking 15 (18.5) 6 (20.0) 0.78
Diabetes treatment
Sulfonylurea 45 (55.6) 15 (50.0) 0.77
Biguanide 16 (19.8) 8 (26.7) 0.36
Thiazolidinedione 24 (29.6) 5 (16.7) 0.21
alpha-glucosidase
inhibitor
36 (44.4) 7 (23.3) 0.06
Insulin 13 (16.0) 6 (20.0) 0.55
Other treatment
Statin 21 (25.9) 9 (30.0) 0.57
antihypertensive
agents
38 (46.3) 13 (44.8) 0.89
EF (%) 67.7 ± 6.2 66.3 ± 6.1 0.56
LVMI (g/m2) 98.9 ± 23.3 88.9 ± 27.2 0.32
MDV baseline (cm/sec) 20 ± 5 22 ± 5 0.08
MDV hyperemia (cm/sec) 62 ± 14 52 ± 13 0.002
CFR 3.09 ± 0.38 2.33 ± 0.13 <0.001
Data are presented as number (%) or mean ± SD.
Abbreviations: BMI body mass index, FBS fasting blood sugar,HbA1c glycated
hemoglobin, eGFR estimated glomerular filtration rate, EF ejection fraction,
LVMI left ventricular mass index, SD standard deviation.
Figure 1 Kaplan-Meier curves for all events (all cause death,
ACS and revascularization) in patients stratified according to
their CFR (≥ 2.5 or < 2.5).
Table 3 Univariate and multivariate predictors of
outcome
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Age 1.06 (1.01-1.12) 0.025 1.04 (0.99-1.10) 0.11
Male gender 2.59 (1.04-7.35) 0.042 2.57 (1.03-7.29) 0.044
Hypertension 1.51 (0.61-4.27) 0.39
Dyslipidemia 1.51 (0.61-4.03) 0.37
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(HR = 3.95, 95% CI = 1.60-10.3, p < 0.01), followed by
male gender (HR = 2.57, 95% CI = 1.03-7.29, p < 0.05).
Cardiac death and ACS (cardiac hard events) occurred
in 9 cases (event rate, 1.4%/year). A univariate Cox
model (Table 4) showed that the predictors of cardiac
hard events were CFR < 2.5 (HR = 4.99, 95% CI = 1.22-24.4,
p < 0.05), age (HR = 1.09, 95% CI = 1.01-1.19, p < 0.05)
and estimated glomerular filtration rate (HR = 0.96, 95%
CI = 0.92-0.99, p < 0.05). Although multivariate analysisTable 2 Event rates in patients stratified by CFR
CFR ≥ 2.5, n = 82 CFR < 2.5, n = 29
All cause death 2 (2.4) 3 (10.3)
Acute coronary syndrome 3 (3.6) 4 (13.8)
Revascularization 3 (3.6) 5 (17.2)
Data are presented as number (%).failed to show CFR < 2.5 as an independent predictor of
cardiac hard events (Table 4), a chi-square test (Fisher’s
exact probability test) indicated that CFR < 2.5 was
significantly related to cardiac hard events (p < 0.01). In
addition, Kaplan-Meier analysis showed that the event
rate was significantly higher (log-lank test, p < 0.01) in
patients with CFR < 2.5 than in patients with CFR ≥ 2.5
(Figure 2).Discussion
The key finding of the present study was that in asymp-
tomatic patients with type 2 diabetes without overt CAD,
CFR assessed by transthoracic Doppler echocardiography
provides long-term prognostic information noninvasively.
Compared with CFR ≥ 2.5, patients with CFR < 2.5 had
significantly worse outcome. Moreover, CFR < 2.5 was a
strong independent predictor of outcome.Smoking 1.19 (0.38-3.14) 0.75
HbA1c 0.97 (0.63-1.42) 0.88
eGFR 1.00 (0.97-1.03) 0.96
EF 0.88 (0.68-1.09) 0.27
LVMI 1.03 (0.98-1.09) 0.25
CFR < 2.5 4.89 (2.02-12.5) <0.001 3.95 (1.60-10.3) 0.003
abbreviations as in Table 1.
Table 4 Univariate and multivariate predictors of cardiac
hard events
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Age 1.09 (1.01-1.19) 0.035 1.05 (0.96-1.15) 0.29
Male 3.01 (0.69-20.6) 0.15
Hypertension 1.88 (0.43-12.8) 0.42
Dyslipidemia 0.73 (0.17-3.12) 0.66
Smoking 0.55 (0.03-3.15) 0.55
HbA1c 0.92 (0.42-1.66) 0.80
eGFR 0.96 (0.92-0.99) 0.035 0.98 (0.94-1.02) 0.34
EF 0.65 (0.28-1.06) 0.10
LVMI 1.03 (0.97-1.13) 0.33
CFR < 2.5 4.99 (1.22-24.4) 0.026 3.47 (0.83-17.4) 0.089
abbreviations as in Table 1.
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The prevalence of diabetes in the Japanese population is
rapidly increasing, and the incidence of cardiac disease
in diabetes is also rising. In fact, the event rate in this
study was higher than that reported in previous studies
[1,11]. Because CAD is a major health concern and the
leading cause of death in patients with type 2 diabetes,
the prevention of CAD is an urgent task of clinicians.
Intensive glycemic control is the basis of diabetes
management to prevent complications such as micro-
and macro-vascular disease. However, the treatment of
diabetes is sometimes difficult because some large clin-
ical trials showed that intensive glucose lowering treat-
ment does not always reduce coronary events [12-14].
Although the current standard of care for diabetes em-
phasizes the reduction of multiple coronary risk factors,
there has also been substantial interest in the identifica-
tion of asymptomatic patients at high risk for developing
CAD in order to optimize therapeutic interventions.
Using CFR, we tried to identify the high risk patientsFigure 2 Kaplan-Meier curves for cardiac hard events (cardiac
death and ACS) in patients stratified according to their CFR
(≥ 2.5 or < 2.5).with diabetes. As indicated in Table 1, the general char-
acteristics including diabetes control of patients with
CFR ≥ 2.5 and CFR < 2.5 were similar. However, Figure 1
showed that the event rate was markedly higher in
patients with CFR < 2.5 than in patients with CFR ≥ 2.5,
indicating that CFR is a valuable tool to identify high-
risk diabetic patients without overt CAD.
CFR and coronary events
Based on the report [15] by Gould et al., CFR has been
widely used as an important index of epicardial coronary
artery stenosis. However, CFR also reflects the function
of the coronary microcirculation in patients without epi-
cardial coronary artery stenosis [16]. Reduced CFR has
been demonstrated in diabetic patients without overt
CAD because of functional and structural alterations of
the coronary microcirculation [17,18]. Reduced CFR has
also been shown even in patients with prediabetes, those
with impaired fasting glucose and those with glucose in-
tolerance [19]. These abnormalities may lead to impaired
vasodilator function, and this may contribute to adverse
future cardiovascular events. In fact, many previous
reports have shown that impaired vasodilator function
assessed by invasive methods adversely affects prognosis
[20-22]. Therefore, assessment of CFR is considered a
reasonable method to stratify the risk of future coronary
events in diabetic patients.
Comparison between adenosine and dipyridamole,
as well as CFR cut-off value
Both adenosine and dipyridamole have been widely used
to induce hyperemic coronary flow and to measure CFR.
Adenosine dilates coronary arterioles through adenosine
A2 receptors by increasing adenylate cyclase and de-
creasing calcium uptake [23]. Dipyridamole inhibits the
cellular uptake of adenosine and indirectly dilates coronary
arteries [24]. Kozàkovà et al. [25] compared the CFR values
obtained with adenosine (0.14 mg/kg/min) and dipyrid-
amole at high (0.84 mg/kg/min) and low (0.56 mg/kg/min)
doses and found that the CFR measured with adenosine
was equivalent to the CFR measured with high-dose
dipyridamole. Lim et al. [26] also found the same results
as Kozàkovà et al. Therefore, the CFRs measured with
adenosine and high-dose dipyridamole are equivalent.
In the present study, patients with CFR < 2.0, a cut-off
value used in previous studies that investigated the prog-
nostic value of reduced CFR on outcomes, were excluded.
Previous studies have reported that CFR < 2.0 with adeno-
sine reflects not only significant epicardial coronary artery
stenosis [7], but also physiological myocardial ischemia
[8]. Although microcirculatory dysfunction in patients
with diabetes causes reduced CFR, it has also been
reported that CFR < 2.0 obtained by transthoracic Doppler
echocardiography had a high predictive value for the
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that included patients with diabetes [27]. On the other
hand, the CFR in an infarct-related vessel is generally low
[28,29], because of microvascular injury and a reduction
in the size of the coronary vascular bed. Therefore, al-
though a CFR < 2.0 is not a precise diagnostic marker for
significant coronary artery stenosis or CAD, we thought
there was a strong likelihood that patients with CFR < 2.0
would have significant coronary artery stenosis or CAD.
For that reason, it may be expected that CFR < 2.0 mea-
sured with high-dose dipyridamole would reflect a poor
prognosis when the study population includes patients
with known CAD and wall motion abnormalities [6]. Be-
cause we wanted to stratify the high-risk patients with dia-
betes but without symptoms or overt CAD in the present
study, it is appropriate that patients with CFR < 2.0 were
excluded from the study.
CFR assessed by transthoracic Doppler echocardiography
Recent developments in transthoracic Doppler echocardi-
ography technology enable the noninvasive visualization
of coronary blood flow and the assessment of CFR. Using
a high-frequency transducer and a reduced velocity range
in color Doppler echocardiography, it is possible to obtain
a high success rate of CFR measurement [7,8]. This tech-
nique has been validated by an intracoronary Doppler flow
wire technique advanced into the coronary vessels [30].
Because transthoracic Doppler echocardiography is nonin-
vasive and does not use radiation, it is useful and suitable
to evaluate the coronary microcirculation in patients with-
out an indication for coronary angiography [31,32]. More-
over, echocardiography is much simpler to perform and
less expensive than myocardial scintigraphy. This tech-
nique is now used worldwide and is established as a non-
invasive tool to assess the coronary circulation [33-35].
Clinical implications
A previous report has shown that half of patients with
asymptomatic type 2 diabetes with microalbuminuria
but without cardiac disease had significant atherosclerosis
[36]. Furthermore, patients with type 2 diabetes without
previous myocardial infarction had as high a risk of myo-
cardial infarction as nondiabetic patients with previous
myocardial infarction [37]. To select appropriate manage-
ment strategies, risk stratification for future events is es-
sential in diabetic patients. Screening by noninvasive CFR
is a valuable, safe and inexpensive tool. On the basis of
our results, patients with CFR < 2.5 have an elevated risk
of future events. Therefore, risk factor control in high-risk
asymptomatic patients with type 2 diabetes is important,
with tight glucose regulation and the use of renin-
angiotensin system blockers, aspirin and lipid-lowering
agents [38]. Moreover, the CFR value might change during
follow-up, resulting from these interventions or diseaseprogression, and the periodic use of this noninvasive
assessment in clinical practice might help to manage
asymptomatic type 2 diabetes.
Limitations
There are some limitations of the present study. First,
CFR was measured only in the LAD. Although measure-
ment of CFR in three coronary arteries is preferable, it
remains technically challenging at the present time.
However, coronary microcirculatory dysfunction affects
the left ventricle globally as well as regionally [39], and
therefore CFR assessment in the LAD is an excellent
option for evaluating the global coronary microcircula-
tion. Second, we excluded the presence of CAD among
the study subjects only by a standard exercise tolerance
test and CFR < 2.0 with Doppler echocardiography.
Compared with wall motion assessment by stress echo-
cardiography or perfusion assessment by stress myocar-
dial scintigraphy, a standard exercise tolerance test has
low sensitivity and specificity to detect CAD. However,
all of the studied patients had both a negative exercise
test and CFR ≥ 2.0, indicating that there was no signifi-
cant LAD stenosis [7,8,27]. Third, although we did not
focus on diastolic function, diastolic dysfunction leads to
impairment of CFR. Various degrees of diastolic dysfunc-
tion have been reported to occur in most patients with
diabetes [40], and diastolic dysfunction might have af-
fected CFR in the present study. Moreover, hypertension
and prehypertension is related to the reduction of CFR.
However, no significant difference was observed in CFR
between patients with and without hypertension in the
present study (2.88 ± 0.50 vs. 2.90 ± 0.44, p = 0.85). This
result may be because of the small number of patients in
the study and/or the effect of treatment on hypertension.
Further investigation of patients with diabetes but with-
out hypertension or prehypertension would provide
new insight into this issue. Lastly, the number of the
study subjects was small compared with previous study
[6]. As a matter of fact, multivariate analysis failed to
show CFR < 2.5 as an independent predictor of cardiac
hard events, probably because of the small number of
subjects included in this study. We carefully selected
asymptomatic diabetic patients that conformed to our
purpose although the subject number was small. How-
ever, large-scale studies are necessary to confirm our
findings.Conclusion
CFR obtained by transthoracic Doppler echocardiography
provides independent prognostic information in asymp-
tomatic patients with type 2 diabetes without overt CAD.
Because patients with CFR < 2.5 had a worse outcome, a
more aggressive intervention is warranted in these patients
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